X4 Pharmaceuticals Inc.
News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...\n more…
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
Globe Newswire BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management...\n more…
HC Wainwright Weighs in on X4 Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:XFOR)
Ticker Report X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at HC Wainwright upped their FY2028 EPS estimates for X4 Pharmaceuticals in a report issued on Friday, August 9th. HC Wainwright...\n more…
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
Seeking Alpha: Transcripts X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript...\n more…
X4 Pharmaceuticals Unveils Corporate Presentation for Investors
TipRanks Financial Blog X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the public. Investors in...\n more…
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Globe Newswire First U.S. commercial sales of XOLREMDI (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected...\n more…